Additionally, recent studies have demonstrated a “tumor sink” effect, where patients with particularly high burden disease demonstrated reduced delivery of 68Ga-PSMA-11 [44] or 177Lu PSMA-617 [45] to target tissues. The gene discussed is FOLH1; the disease is neoplasm.